Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma

• Main Authors: Jing-Yu Hou (Author), Ya-ting Xiao (Author), Jing-Bo Huang (Author), Xin-Hua Jiang (Author), Kai Jiang (Author), Xun Li (Author), Li Xu (Author), Min-Shan Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The RESORCE trial reported that regorafenib was effective as the second-line treatment for patients with hepatocellular carcinoma (HCC) after progression on sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice.Objective: We...